display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
malignant mesothelioma (mMS) - 2nd line (L2)
malignant mesothelioma (mMS) - 2nd line (L2)
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab DETERMINE
anti-PD-(L)1
nivolumab based treatment
nivolumab alone CONFIRM

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons